期刊文献+

高血压药对糖尿病肾病血液透析患者代谢的影响

A comparative study of the effects of different antihypertension drugs to material metabolism of Type 2 Diabetic hemodialysis patients
下载PDF
导出
摘要 目的比较血管紧张素转换酶抑制剂(ACEI)、钙离子拮抗剂(CCB)和β-受体阻滞剂等抗高血压药对糖尿病肾病及高血压透析患者的血糖和代谢的影响。方法糖尿病肾病血液透析患者分别经福辛普利(Fosinopril)、维拉帕米(Verapamil)和普萘洛尔(Propranol01)治疗5个月后记录透析前后心率和血压改变,检测透析前空腹血糖、糖化血红蛋白(HbA1c)、果糖胺、胰岛素、胆固醇和甘油三脂等。结果Fosinopril、Verapamil对血糖及物质代谢无不良影响,Propranolol可引起血糖、果糖胺、HbA1c和甘油三脂升高及透析过程中低血压和心率减慢。结论Fosinopril、Verapamil和Propranolol均为控制糖尿病肾病透析患者轻、中度高血压的较可靠药物,且Fosinopril和Verapamil对糖尿病患者血糖和物质代谢无不良影响。 Objective To compare the effects of antihypertension drugs, such as ACEI, CCB and beta blockers on the material metabolism of hemodialysis patients with T2DM and hypertension. Method After treatments with Fosinopril, Verapamil and Propranolol respectively, The changes of heart rate and blood pressure were recorded before and after hemodialysis; the changes of plasma glucose, hemoglobin A1C, fructosamin, serum insulin, cholesterol and triglycerides were compared as well. Results Fosinopril, Verapamil showed no harmful effects on plasma glucose and metabolism; while Propranolol resultel an increase of plasma glucose, fructosamin, hemoglobin A1C and triglyceride, and decrease of blood pressure and slower of heart rate during the hemodialysis. Conclusions For the hemodialysis patients with T2DM, Fosinopril, Verapamil and Propranolol are reliable drugs to control mild and moderate hypertension. Furthermore, Fosinopril and Verapamil have no bad effect to the plasma glucose and material metabolism.
出处 《临床肾脏病杂志》 2006年第2期70-72,共3页 Journal Of Clinical Nephrology
关键词 血液透析 糖尿病 代谢 高血压 Hemodialysis Diabetes Mellitus Material metabolism Hypertension
  • 相关文献

参考文献6

二级参考文献27

  • 1王质刚.应当重视血液透析中看不见的事件[J].中国血液净化,2004,3(10):523-525. 被引量:8
  • 2尹良红,陈玉琼,林日英,林利雅,陈湛华,郑绮宜.应用心导纳图求积法原理检测透析病人血透前后心功能改变[J].中华肾脏病杂志,1995,11(3):166-167. 被引量:14
  • 3季大玺 谢红浪.血液透析心血管并发症[A].林善炎主编.当代肾脏病学[C].上海:上海科技教育出版社,2001.838~9.
  • 4沈清瑞 毛海萍 见:沈清瑞 叶任高 余学清主编.心血管并发症[A].见:沈清瑞,叶任高,余学清主编.血液透析的临床应用[C].北京:人民卫生出版社,1999.89~90.
  • 5[1]Fisenberg B,Murata G,Tzamalokas A,et al.Gastroparesis in diabetics on chronic dialysis:Clinical and laboratory associations and predictive features.Nephron,1995,70:296
  • 6[3]Breyer JA,Diabetic nephropathy in insulin-dependent patients.Am J Kid Dis,1992,20:533
  • 7[4]Ritz E,Stefanski A. Diabetic nephropaphy in type II diabetes. Am J Kid Dis,1996,27:167
  • 8[5]Mattem W,McCaghieW, Rigby R,et al. Selection of ESRD treatment:An Intemational Study.Am J Kid Dis, 1989,13:457
  • 9[6]USRDS Annual Data Report.Bethesda, Maryland:The National Institute of Health,National Institute of Diabetes and Digestive and Kidney Diseases,1992
  • 10张华吉 李环.Zeneca公司的赖诺普利成为处方量最大的ACEI.国外药迅,1999,4:24-24.

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部